Adverum Biotechnologies Inc (ADVM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Adverum Biotechnologies Inc (ADVM) has a cash flow conversion efficiency ratio of 0.505x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.11 Million) by net assets ($-55.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Adverum Biotechnologies Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Adverum Biotechnologies Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Adverum Biotechnologies Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Adverum Biotechnologies Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adverum Biotechnologies Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ecograf Ltd
AU:EGR
|
-0.015x |
|
Merck Tbk
JK:MERK
|
0.165x |
|
CI Holdings Bhd
KLSE:2828
|
0.112x |
|
Grupo Greening 2022 SA
MC:GGR
|
N/A |
|
New Asia Construction & Development Corp
TW:2516
|
-0.226x |
|
Centro de Imagem Diagnósticos S.A
SA:AALR3
|
0.071x |
|
SHANGHAI FUDAN H YC-,10
F:FDY
|
N/A |
|
Raba Jarmuipari Holding Nyrt
BUD:RABA
|
0.085x |
Annual Cash Flow Conversion Efficiency for Adverum Biotechnologies Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Adverum Biotechnologies Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see ADVM stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $70.71 Million | $-92.46 Million | -1.308x | +3.31% |
| 2023-12-31 | $67.22 Million | $-90.90 Million | -1.352x | -127.09% |
| 2022-12-31 | $181.52 Million | $-108.09 Million | -0.595x | -74.61% |
| 2021-12-31 | $316.19 Million | $-107.83 Million | -0.341x | -86.82% |
| 2020-12-31 | $434.35 Million | $-79.29 Million | -0.183x | +35.04% |
| 2019-12-31 | $174.96 Million | $-49.17 Million | -0.281x | -4.77% |
| 2018-12-31 | $201.17 Million | $-53.96 Million | -0.268x | -8.69% |
| 2017-12-31 | $184.03 Million | $-45.42 Million | -0.247x | -38.70% |
| 2016-12-31 | $215.60 Million | $-38.37 Million | -0.178x | -27.20% |
| 2015-12-31 | $252.59 Million | $-35.34 Million | -0.140x | -270.27% |
| 2014-12-31 | $149.48 Million | $-5.65 Million | -0.038x | -100.38% |
| 2013-12-31 | $-218.00K | $-2.17 Million | 9.977x | +685.09% |
| 2012-12-31 | $-997.00K | $-1.27 Million | 1.271x | -- |
About Adverum Biotechnologies Inc
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is … Read more